CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027. Novo Nordisk's blockbuster diabetes drug ...

In a 72-week study, Zepbound's mean weight loss was 20.2%, while Wegovy's was 13.7% ... making it a good target for income-seeking investors. In short, Novo Nordisk is a solid long-term pick.

Drugs like Ozempic, Wegovy, and Mounjaro have demonstrated remarkable efficacy, not only in lowering blood sugar but also in facilitating substantial weight loss. Clinical trials show that ...

Hims & Hers offers compounded versions of the weight-loss drug semaglutide, which was developed by Novo Nordisk and is typically sold under the names Wegovy and Ozempic. The Partnership for Safe ...

Sales of weight loss drug Wegovy more than doubled in the final ... and some online pharmacies have set targets for how many prescriptions should be processed per hour. The GPhC has told online ...

MET-097i has a half-life of 15 to 16 days which trumps the reported time of both tirzepatide, marketed as Zepbound, and semaglutide, marketed as Wegovy, for weight loss. GlobalData senior analyst ...

Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today. From reproductive rights to climate change to Big Tech, The ...

Drug industry calls out telehealth company Hims & Hers' Super Bowl ad touting its knock-off weight loss medications.

Novo Nordisk is planning a new Phase III trial for CagriSema, the company’s next-generation obesity drug touted as a potential successor to Wegovy (semaglutide), as the company aims to quell ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.